Global Precision Medicine Software Market to Reach $3.2 Billion by 2027
ReportLinker
In the changed post COVID-19 business landscape, the global market for Precision Medicine Software estimated at US$1. 6 Billion in the year 2020, is projected to reach a revised size of US$3. 2 Billion by 2027, growing at aCAGR of 10% over the period 2020-2027.
New York, Jan. 04, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Precision Medicine Software Industry” –
On-Premise, one of the segments analyzed in the report, is projected to record 9.2% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cloud segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
The U.S. Market is Estimated at $444.8 Million, While China is Forecast to Grow at 13.7% CAGR
The Precision Medicine Software market in the U.S. is estimated at US$444.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$668.5 Million by the year 2027 trailing a CAGR of 13.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.
Select Competitors (Total 34 Featured) –
2bprecise, LLC
Fabric Genomics, Inc.
Foundation Medicine, Inc.
Gene42, Inc.
Human Longevity, Inc.
Lifeomic Health, LLC
N-Of-One, Inc. (A Subsidiary of Qiagen N.V.)
Pieriandx, Inc.
Sophia Genetics Sa
Sunquest Information Systems, Inc.
Syapse, Inc.
Translational Software Inc.
Read the full report:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Precision Medicine Software – Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Precision Medicine Software by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Precision Medicine Software
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Precision Medicine
Software by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2021 & 2027
Table 4: World Recent Past, Current & Future Analysis for
On-Premise by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for On-Premise by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for On-Premise by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for Cloud
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Cloud by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Cloud by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 10: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Other End-Uses by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Other End-Uses by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 13: World Recent Past, Current & Future Analysis for
Healthcare Providers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Healthcare Providers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Healthcare Providers by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 16: World Recent Past, Current & Future Analysis for
Research Centers & Academic Institutes by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Research Centers & Academic
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Research Centers &
Academic Institutes by Geographic Region – Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2021 & 2027
Table 19: World Recent Past, Current & Future Analysis for
Pharma & Biotech Companies by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Pharma & Biotech Companies
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Pharma & Biotech
Companies by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027
Table 22: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Oncology by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for Oncology by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 25: World Recent Past, Current & Future Analysis for
Pharmacogenomics by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 26: World Historic Review for Pharmacogenomics by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 27: World 15-Year Perspective for Pharmacogenomics by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 28: World Recent Past, Current & Future Analysis for Rare
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 29: World Historic Review for Rare Diseases by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 30: World 15-Year Perspective for Rare Diseases by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 31: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR
Table 32: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 33: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 34: World Precision Medicine Software Market Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in the United States for 2022
(E)
Table 35: USA Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 36: USA Historic Review for Precision Medicine Software
by Deployment – On-Premise and Cloud Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 37: USA 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 38: USA Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 39: USA Historic Review for Precision Medicine Software
by End-Use – Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 40: USA 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 41: USA Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 42: USA Historic Review for Precision Medicine Software
by Application – Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 43: USA 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
CANADA
Table 44: Canada Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 45: Canada Historic Review for Precision Medicine
Software by Deployment – On-Premise and Cloud Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 46: Canada 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 47: Canada Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 48: Canada Historic Review for Precision Medicine
Software by End-Use – Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 49: Canada 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 50: Canada Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 51: Canada Historic Review for Precision Medicine
Software by Application – Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 52: Canada 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
JAPAN
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in Japan for 2022 (E)
Table 53: Japan Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 54: Japan Historic Review for Precision Medicine Software
by Deployment – On-Premise and Cloud Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 55: Japan 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 56: Japan Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 57: Japan Historic Review for Precision Medicine Software
by End-Use – Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 58: Japan 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 59: Japan Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 60: Japan Historic Review for Precision Medicine Software
by Application – Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 61: Japan 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
CHINA
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in China for 2022 (E)
Table 62: China Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 63: China Historic Review for Precision Medicine Software
by Deployment – On-Premise and Cloud Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 64: China 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 65: China Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 66: China Historic Review for Precision Medicine Software
by End-Use – Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 67: China 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 68: China Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 69: China Historic Review for Precision Medicine Software
by Application – Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 70: China 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
EUROPE
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in Europe for 2022 (E)
Table 71: Europe Recent Past, Current & Future Analysis for
Precision Medicine Software by Geographic Region – France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 72: Europe Historic Review for Precision Medicine
Software by Geographic Region – France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 73: Europe 15-Year Perspective for Precision Medicine
Software by Geographic Region – Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2021 & 2027
Table 74: Europe Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 75: Europe Historic Review for Precision Medicine
Software by Deployment – On-Premise and Cloud Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 76: Europe 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 77: Europe Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 78: Europe Historic Review for Precision Medicine
Software by End-Use – Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 79: Europe 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 80: Europe Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 81: Europe Historic Review for Precision Medicine
Software by Application – Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 82: Europe 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
FRANCE
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in France for 2022 (E)
Table 83: France Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 84: France Historic Review for Precision Medicine
Software by Deployment – On-Premise and Cloud Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 85: France 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 86: France Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 87: France Historic Review for Precision Medicine
Software by End-Use – Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 88: France 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 89: France Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 90: France Historic Review for Precision Medicine
Software by Application – Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 91: France 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
GERMANY
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in Germany for 2022 (E)
Table 92: Germany Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 93: Germany Historic Review for Precision Medicine
Software by Deployment – On-Premise and Cloud Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 94: Germany 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 95: Germany Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 96: Germany Historic Review for Precision Medicine
Software by End-Use – Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 97: Germany 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 98: Germany Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 99: Germany Historic Review for Precision Medicine
Software by Application – Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 100: Germany 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
ITALY
Table 101: Italy Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 102: Italy Historic Review for Precision Medicine
Software by Deployment – On-Premise and Cloud Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 103: Italy 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 104: Italy Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 105: Italy Historic Review for Precision Medicine
Software by End-Use – Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 106: Italy 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 107: Italy Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 108: Italy Historic Review for Precision Medicine
Software by Application – Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 109: Italy 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
UNITED KINGDOM
Precision Medicine Software Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in the United Kingdom for 2022
(E)
Table 110: UK Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 111: UK Historic Review for Precision Medicine Software
by Deployment – On-Premise and Cloud Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 112: UK 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 113: UK Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
and Pharma & Biotech Companies – Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 114: UK Historic Review for Precision Medicine Software
by End-Use – Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 115: UK 15-Year Perspective for Precision Medicine
Software by End-Use – Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2021 & 2027
Table 116: UK Recent Past, Current & Future Analysis for
Precision Medicine Software by Application – Oncology,
Pharmacogenomics, Rare Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 117: UK Historic Review for Precision Medicine Software
by Application – Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 118: UK 15-Year Perspective for Precision Medicine
Software by Application – Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2021 & 2027
SPAIN
Table 119: Spain Recent Past, Current & Future Analysis for
Precision Medicine Software by Deployment – On-Premise and
Cloud – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR
Table 120: Spain Historic Review for Precision Medicine
Software by Deployment – On-Premise and Cloud Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 121: Spain 15-Year Perspective for Precision Medicine
Software by Deployment – Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2021 & 2027
Table 122: Spain Recent Past, Current & Future Analysis for
Precision Medicine Software by End-Use – Other End-Uses,
Healthcare Providers, Research Centers & Academic Institutes
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report:
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Story continues
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
No Byline Policy
Editorial Guidelines
Corrections Policy
Source